JP2025179094A5 - - Google Patents
Info
- Publication number
- JP2025179094A5 JP2025179094A5 JP2025138920A JP2025138920A JP2025179094A5 JP 2025179094 A5 JP2025179094 A5 JP 2025179094A5 JP 2025138920 A JP2025138920 A JP 2025138920A JP 2025138920 A JP2025138920 A JP 2025138920A JP 2025179094 A5 JP2025179094 A5 JP 2025179094A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- weight
- morpholinophenyl
- ylamino
- pyrazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063009623P | 2020-04-14 | 2020-04-14 | |
| US63/009,623 | 2020-04-14 | ||
| US202063014277P | 2020-04-23 | 2020-04-23 | |
| US63/014,277 | 2020-04-23 | ||
| JP2022562451A JP7787824B2 (ja) | 2020-04-14 | 2021-04-13 | アミノピリミジン誘導体若しくはその薬学的に許容される塩、水和物、又は溶媒和物を含む経口投与のための医薬組成物 |
| PCT/IB2021/053035 WO2021209893A1 (en) | 2020-04-14 | 2021-04-13 | Pharmaceutical composition for oral administration comprising amin op yrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022562451A Division JP7787824B2 (ja) | 2020-04-14 | 2021-04-13 | アミノピリミジン誘導体若しくはその薬学的に許容される塩、水和物、又は溶媒和物を含む経口投与のための医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025179094A JP2025179094A (ja) | 2025-12-09 |
| JP2025179094A5 true JP2025179094A5 (https=) | 2025-12-16 |
Family
ID=75562794
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022562451A Active JP7787824B2 (ja) | 2020-04-14 | 2021-04-13 | アミノピリミジン誘導体若しくはその薬学的に許容される塩、水和物、又は溶媒和物を含む経口投与のための医薬組成物 |
| JP2025138920A Pending JP2025179094A (ja) | 2020-04-14 | 2025-08-22 | アミノピリミジン誘導体若しくはその薬学的に許容される塩、水和物、又は溶媒和物を含む経口投与のための医薬組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022562451A Active JP7787824B2 (ja) | 2020-04-14 | 2021-04-13 | アミノピリミジン誘導体若しくはその薬学的に許容される塩、水和物、又は溶媒和物を含む経口投与のための医薬組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12138351B2 (https=) |
| EP (1) | EP4135669A1 (https=) |
| JP (2) | JP7787824B2 (https=) |
| KR (1) | KR20230002656A (https=) |
| CN (1) | CN115484937A (https=) |
| AU (2) | AU2021257662B2 (https=) |
| CA (1) | CA3180184A1 (https=) |
| IL (1) | IL297240A (https=) |
| MX (1) | MX2022012898A (https=) |
| PH (1) | PH12022552454A1 (https=) |
| UY (1) | UY39171A (https=) |
| WO (1) | WO2021209893A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200043618A (ko) * | 2018-10-18 | 2020-04-28 | 주식회사유한양행 | 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물 |
| WO2022253261A1 (zh) * | 2021-06-01 | 2022-12-08 | 杭州领业医药科技有限公司 | Lazertinib甲磺酸盐的水合物晶型及其制备方法和用途 |
| CN118251220A (zh) * | 2022-01-19 | 2024-06-25 | 江苏奥赛康药业有限公司 | 一种包含嘧啶基团的三并环类化合物的组合物及其制备方法和应用 |
| CA3228195A1 (en) | 2023-05-23 | 2025-06-30 | Janssen Biotech, Inc. | Methods for treatment of non-small cell lung cancer (nsclc) |
| WO2025052273A1 (en) | 2023-09-05 | 2025-03-13 | Janssen Biotech, Inc. | Methods of treating non-small cell lung cancer |
| WO2026042017A1 (en) | 2024-08-19 | 2026-02-26 | Janssen Biotech, Inc. | Amivantamab in combination with lazertinib for the treatment of non-small cell lung cancer (nsclc) |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6437006B1 (en) * | 1999-09-27 | 2002-08-20 | American Cyanamid Company | Pharmaceutical carrier formulation |
| US6399591B1 (en) * | 2000-01-19 | 2002-06-04 | Yung-Shin Pharmaceutical Ind. Co., Ltd. | Chargeable pharmaceutical tablets |
| WO2008057266A2 (en) * | 2006-10-27 | 2008-05-15 | Fmc Corporation | Dry granulation binders, products, and use thereof |
| EP2198857A1 (en) * | 2008-12-19 | 2010-06-23 | Ratiopharm GmbH | Oral dispersible tablet |
| US9278063B2 (en) * | 2009-12-11 | 2016-03-08 | Sumitomo Dainippon Pharma Co., Ltd. | Press-coated orally-disintegrating tablets |
| JP2013523833A (ja) * | 2010-04-07 | 2013-06-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の医薬組成物およびその投与 |
| CN113201073A (zh) | 2012-11-21 | 2021-08-03 | 詹森生物科技公司 | 双特异性EGFR/c-Met抗体 |
| WO2015006753A2 (en) * | 2013-07-12 | 2015-01-15 | The Regents Of The University Of California | Therapies for diseases caused by arthropod-borne parasites |
| JP6581088B2 (ja) * | 2013-12-12 | 2019-09-25 | アルミラル・ソシエダッド・アノニマＡｌｍｉｒａｌｌ， Ｓ．Ａ． | フマル酸ジメチルを含む医薬組成物 |
| GB201402070D0 (en) * | 2014-02-07 | 2014-03-26 | Galapagos Nv | Pharmaceutical compositions for the treatment of inflammatory disorders |
| EP3929190B1 (en) | 2014-10-13 | 2024-12-25 | Yuhan Corporation | Compounds and compositions for modulating egfr mutant kinase activities |
| CN109310677A (zh) | 2016-04-07 | 2019-02-05 | 凯莫森特里克斯股份有限公司 | 通过联合施用ccr1拮抗剂与pd-1抑制剂或pd-l1拮抗剂降低肿瘤负荷 |
| KR20230169458A (ko) * | 2017-01-20 | 2023-12-15 | 엑셀리시스, 인코포레이티드 | 암을 치료하기 위한 카보잔티닙 및 아테졸리주맙의 조합 |
| CN110520110A (zh) * | 2017-03-08 | 2019-11-29 | 阿瑞雅德制药公司 | 包含5-氯-n4-[2-(二甲基磷酰基)苯基]-n2-{2-甲氧基-4-[4-(4-甲基哌嗪-1-基)哌啶-1-基]苯基}嘧啶-2,4-二胺的药物制剂 |
| AR111469A1 (es) * | 2017-04-21 | 2019-07-17 | Yuhan Corp | Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma |
| FI3658552T3 (fi) | 2017-07-28 | 2023-11-16 | Yuhan Corp | Menetelmä n-(5-((4-(4-((dimetyyliamino)metyyli)-3-fenyyli-1h-pyratsol-1-yyli)pyrimidin-2-yyli)amino)-4-metoksi-2-morfolinofenyyli)akryyliamidin valmistamiseksi saattamalla vastaava amiini reagoimaan 3-halopropionyylikloridin kanssa |
| EP3658553B1 (en) | 2017-07-28 | 2022-06-15 | Yuhan Corporation | Intermediates useful for the synthesis of aminopyrimidine derivatives, process for preparing the same, and process for preparing aminopyrimidine derivatives using the same |
| ES2959967T3 (es) | 2017-07-28 | 2024-02-29 | Yuhan Corp | Procedimiento de preparación deN-(5-(4-(4-formil-3-fenil-1h-pirazol-1-il)pirimidin-2-ilamino)-4-metoxi-2-morfolinofenil)acrilamida |
| CN110580014B (zh) * | 2018-06-11 | 2021-03-30 | 北京京东尚科信息技术有限公司 | 用于控制自动导引运输车的方法、装置和系统 |
| JP7455807B2 (ja) * | 2018-07-20 | 2024-03-26 | アイメリーズ ユーエスエー，インコーポレーテッド | 鋳造砂廃棄物からの砂、ベントナイト、及び有機物の回収 |
| KR20200043618A (ko) | 2018-10-18 | 2020-04-28 | 주식회사유한양행 | 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물 |
| CA3136632A1 (en) * | 2019-04-11 | 2020-10-15 | Goldfinch Bio, Inc. | Spray-dried formulation of a pyridazinone trpc5 inhibitor |
| FI3920891T3 (fi) * | 2019-04-17 | 2024-03-19 | Nordiccan As | Nopeasti hajoavat kannabinoiditabletit |
| US11850248B2 (en) | 2019-05-14 | 2023-12-26 | Yuhan Corporation | Therapies with 3rd generation EGFR tyrosine kinase inhibitors |
| AU2020319662B2 (en) * | 2019-07-31 | 2024-02-29 | F. Hoffmann-La Roche Ag | New pharmaceutical formulation |
-
2021
- 2021-04-13 PH PH1/2022/552454A patent/PH12022552454A1/en unknown
- 2021-04-13 US US17/228,753 patent/US12138351B2/en active Active
- 2021-04-13 CA CA3180184A patent/CA3180184A1/en active Pending
- 2021-04-13 KR KR1020227039484A patent/KR20230002656A/ko active Pending
- 2021-04-13 CN CN202180028642.0A patent/CN115484937A/zh active Pending
- 2021-04-13 UY UY0001039171A patent/UY39171A/es unknown
- 2021-04-13 AU AU2021257662A patent/AU2021257662B2/en active Active
- 2021-04-13 MX MX2022012898A patent/MX2022012898A/es unknown
- 2021-04-13 JP JP2022562451A patent/JP7787824B2/ja active Active
- 2021-04-13 WO PCT/IB2021/053035 patent/WO2021209893A1/en not_active Ceased
- 2021-04-13 EP EP21719733.4A patent/EP4135669A1/en active Pending
- 2021-04-13 IL IL297240A patent/IL297240A/en unknown
-
2024
- 2024-11-07 US US18/939,761 patent/US20250177311A1/en active Pending
-
2025
- 2025-05-09 AU AU2025203347A patent/AU2025203347A1/en active Pending
- 2025-08-22 JP JP2025138920A patent/JP2025179094A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025179094A5 (https=) | ||
| US8673945B2 (en) | Solid pharmaceutical composition comprising amlodipine and losartan | |
| US20160129008A1 (en) | Solid Dosage Form of Olmesartan Medoxomil and Amlodipine | |
| US20190030033A1 (en) | Pharmaceutical composition containing jak kinase inhibitor or pharmaceutically acceptable salt thereof | |
| US20220211705A1 (en) | Pharmaceutical compositions comprising afatinib | |
| HRP20040403A2 (en) | Polymorphous form of rimonabant, preparation method and pharmaceutical compositions containing same | |
| FI3866767T3 (fi) | Aminopyrimidiinijohdannaista tai sen suolaa käsittävä farmaseuttinen koostumus suun kautta annostelua varten | |
| JP2014074067A (ja) | メシル酸イマチニブのｆ、ｇ、ｈ、ｉおよびｋ結晶形 | |
| JP2020073513A (ja) | α，ω‐二置換ジヒドロキシシクロペンチル化合物の固体形態、並びにその製造及び使用方法 | |
| TWI574690B (zh) | 立即釋放４－甲基－３［［４－（３－吡啶基）－２－嘧啶基］胺基］－ｎ－［５－（４－甲基－１ｈ－咪唑－１－基）－３－（三氟甲基）苯基］苯甲醯胺調配物 | |
| US6001845A (en) | Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction | |
| UA69441C2 (uk) | Саредутант як агент для лікування або попередження основних депресивних розладів | |
| FI3993777T3 (fi) | Kompressoidut masitentaanikoostumukset, menetelmät ja niiden käytöt | |
| US6136818A (en) | Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction | |
| JPH05194228A (ja) | ダピプラゾール含有経口投与用固体医薬組成物 | |
| WO2013100870A1 (en) | New antipsychotic compositions | |
| JP2010516712A5 (https=) | ||
| JP7437039B2 (ja) | 錠剤 | |
| JP2024090218A (ja) | 崩壊遅延を改善したゾニサミド含有口腔内速崩壊錠 | |
| JP6939228B2 (ja) | 口腔内崩壊錠の製造方法 | |
| JP2022097443A (ja) | ビラスチンを含有する口腔内崩壊錠 | |
| GB2471970A (en) | Composition comprising olmesartan medoxomil, amlodipine and hydrochlorothiazide | |
| NZ774402B2 (en) | Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt | |
| KR20160014618A (ko) | 유기산과의 아고멜라틴 공-결정체 형태로 아고멜라틴을 포함하는 약제학적 제형 | |
| WO2013081567A1 (en) | Effervescent antipsychotic formulations |